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Abstract
Background—Adjuvant endocrine therapy for breast cancer reduces recurrence and improves 
survival rates. Many patients never start treatment or discontinue prematurely. A better 
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understanding of factors associated with endocrine therapy initiation and persistence could inform 
practitioners how to support patients.
Methods—We analyzed data from a longitudinal study of 2,268 women diagnosed with breast 
cancer and reported to the Metropolitan Detroit and Los Angeles SEER cancer registries in 
2005-2007. Patients were surveyed approximately both 9 months and 4 years after diagnosis. At 4-
years, patients were asked if they had initiated endocrine therapy, terminated therapy, or were 
currently taking therapy (defined as persistence). Multivariable logistic regression models 
examined factors associated with initiation and persistence.
Results—Of the 743 patients eligible for endocrine therapy, 80 (10.8%) never initiated therapy, 
112 (15.1%) started therapy but discontinued prematurely, and 551 (74.2%) continued use at the 
second time point. Compared with whites, Latinas (OR 2.80, 95% CI 1.08-7.23) and black women 
(OR 3.63, 95% CI 1.22-10.78) were more likely to initiate therapy. Other factors associated with 
initiation included worry about recurrence (OR 3.54, 95% CI 1.31 – 9.56) and inadequate 
information about side effects (OR 0.24, 95% CI 0.10 – 0.55). Factors associated with persistence 
included two or more medications taken weekly (OR 4.19, 95% CI 2.28-7.68) and increased age 
(OR 0.98, 95% CI 0.95-0.99).
Conclusions—Enhanced patient education about potential side effects and the effectiveness of 
adjuvant endocrine therapy in improving outcomes may improve initiation and persistence rates 
and optimize breast cancer survival.
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Introduction
Adjuvant endocrine therapy for invasive breast cancer has well-established benefits in 
reducing recurrence and improving survival. Tamoxifen [1] and aromatase inhibitors [2] 
reduce mortality and longer duration of therapy provides greater benefit versus shorter 
duration [1, 3-5]. Despite this, not all eligible patients initiate (ever take) or persist with 
(defined as completing a prescribed course of clinically indicated) endocrine therapy [6-9].
The favorable efficacy data have culminated in clinical practice guidelines that recommend 
five years of adjuvant endocrine therapy – tamoxifen and, in postmenopausal women, 
aromatase inhibitors or sequential therapy with both tamoxifen and aromatase inhibitors for 
all women who have a hormone receptor-positive tumor over 1 centimeter [10-12]. Two 
clinical trials recently documented efficacy when endocrine therapy was extended to ten 
years [13-14]. These data may encourage clinicians to prescribe therapy beyond the current 
five year recommendation. Common side effects of all agents include hot flashes and 
vaginal discharge or dryness. Serious side effects, such as thromboembolism and uterine 
cancer, have been reported with tamoxifen. Although the aromatase inhibitors are generally 
well-tolerated[15], their use can cause loss of bone mineral density and arthralgias[16].
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Initiation of treatment and persistence remains a continuing challenge to clinicians. While 
rates of guideline-concordant prescribing of adjuvant hormonal therapy are high[17-19], a 
number of studies have documented that long term persistence with prescribed endocrine 
therapy for breast cancer is alarmingly low [6-9, 20-26]. Between 33% and 40% of patients 
terminate therapy before the recommended five-year period, a discontinuation rate that is 
substantively higher than that reported in clinical trials [27]. The high termination rate is 
consistent, however, with studies of medication use for other chronic conditions [28-29]. 
Chronic care researchers have proposed several factors that may influence with suboptimal 
use of endocrine therapy. Patient attributes such as older age, greater uncertainty about the 
marginal benefit of treatment, clinical indication for treatment, and more comorbid 
conditions have been associated with lower persistence, as have side-effects from therapy 
[21-22, 30] and higher out-of-pocket costs [31-33].
There are noteworthy gaps in our understanding of adjuvant endocrine therapy initiation and 
persistence. These include a lack of studies investigating endocrine therapy use in 
populations not identified through clinical trials, convenience samples, or enrolled in 
specific health plans, the absence of data obtained directly from patients, and a reliance on 
cross-sectional designs. To address these gaps, we examined data on factors associated with 
endocrine therapy initiation and persistence in women diagnosed with invasive breast 
cancer, selected from two SEER (Surveillance, Epidemiology and End Results) population-
based cancer registries in the US, who participated in a longitudinal study.
Methods
Study Sample and Data Collection
Our sampling strategy has been reported previously [34]. Women who lived in Los Angeles 
county or the Detroit metropolitan area who were between 20-79 years of age, diagnosed 
with AJCC stages I-III breast cancer or ductal carcinoma in situ (DCIS) between June 2005 
and February 2007, and reported to the Los Angeles County and Metropolitan Detroit SEER 
tumor registries were eligible to participate. The recruitment strategy included a 20% 
random sample of non-Hispanic whites, all eligible black patients in Detroit and Los 
Angeles, and all eligible Latinas in Los Angeles. We did not survey Asian women in Los 
Angeles due to a concurrent study in that population. We excluded women with diagnoses of 
inflammatory breast cancer or metastatic disease at presentation, women for whom we did 
not have race/ethnicity information, and women who could not complete a questionnaire in 
English or Spanish. The final analyses included only women with invasive disease that was 
estrogen or progesterone receptive positive. We excluded women who were too ill or 
incompetent or whose doctor refused permission to contact the participant. We obtained a 
73.1% response rate [34].
We used a modified version of the Dillman survey method to maximize response rates, 
which involved intensive telephone follow-up, second mailings of materials, and phone 
interviews when required [35]. Women were surveyed at two points in time: a baseline 
survey approximately 9 months after diagnosis (range of 5 to 14 months after diagnosis) and 
a follow up survey approximately 4 years later (range of 36 to 65 months after initial 
diagnosis). After physician notification of our intention to contact their patients, we mailed 
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eligible patients a recruitment letter, questionnaire, and a $10 cash gift. Non-responders 
received a postcard reminder at 3 weeks, followed by a telephone call and an option to 
complete the questionnaire by telephone. To increase Latina participation, we used surnames 
to identify women who were likely to report Latina ethnicity and provided study materials in 
both English and Spanish [36]. Clinical data from the SEER registries were merged with 
survey data obtained by patients at both time points. Study procedures received approval 
from the Institutional Review Boards of the University of Michigan, the University of 
Southern California and Wayne State University.
Measures
Dependent Variables—The dependent variables of endocrine therapy initiation and 
persistence were obtained from the follow up questionnaire completed approximately four 
years after diagnosis. First, we asked women if they had taken any of the following 
hormonal breast cancer medicines in the past week: exemestane (Aromasin), letrozole 
(Femara), anastrozole (Arimedex), tamoxifen (Nolvadex), or raloxifene (Evista). 
Respondents who answered “yes” were classified as being persistent with endocrine therapy. 
Respondents who answered “no” were asked if they had ever taken any of the medications 
listed above. Those who answered “yes” were classified as having initiated therapy. The 
third group was comprised of those women who reported “no” to having taken endocrine 
therapy in the past week and also reported “no” to ever taking endocrine therapy.
Independent Variables—The SEER registries provided the following information: age at 
diagnosis, race/ethnicity (white, Latina, black), stage (I, II, III), grade (1, 2, 3, or unknown), 
tumor size (in cm), and estrogen/progesterone receptor status. The baseline questionnaire 
completed by patients approximately 9 months after diagnosis assessed the presence of 
comorbid conditions (none, 1, 2 or more), education (high school or less, some college, 
college graduate), weight (in pounds), and married or partnered (yes/no). In addition to the 
outcome measures defined above, the follow up questionnaire completed approximately 4 
years after diagnosis queried patients on their primary provider for cancer follow up 
(surgeon, medical oncologist, or other), and whether patients had received enough 
information from their doctor about endocrine therapy (yes/no). Number of medications 
taken weekly (none, 1, 2 or more) was asked at the follow up survey and was included in 
analyses of the persistence outcome only. Two scales were included in the follow-up 
questionnaire to measure medication beliefs and worry about recurrence. To assess 
medication beliefs, items modified from the previously-validated beliefs about medicine 
questionnaire [37] assessed patients’ agreement about statements with regard to medicine, 
including “medicines do more harm than good.” Five items on a five-point Likert scale were 
used and a mean score (range of 1-5), with higher scores reflecting more positive beliefs 
toward medication use. As in our previous report [38], worry about recurrence was 
measured on a five-point Likert scale from three items: concern the cancer would recur in 
the same breast, the other breast, or in another part of the body. An overall worry score was 
calculated as a mean across the three items. Higher scores reflect greater worry about 
recurrence (range 1-5; Cronbach alpha = 0.86). For modeling purposes, we categorized the 
worry about recurrence score into three levels: low (≤ 2.0 on a 5-point scale), medium 
(2.1-4.0), and high (>4.0). Finally, women who never initiated endocrine therapy or 
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discontinued therapy prematurely were asked their reasons for doing so. These included 
physician instructions to discontinue, concerns for side effects, and cost/insurance issues. 
Participants could select multiple responses to this question.
Statistical Analyses
We first calculated descriptive statistics for the entire analytical sample and the subgroups of 
women who initiated or persisted with therapy. To compare the patients who initiated (or 
persisted) with those who did not initiate (or persist), we used Chi-square tests for 
categorical variables and ANOVA for continuous variables. Several clinical variables that 
may influence use of endocrine therapy were included in all analyses. These include tumor 
stage, tumor grade, and age. Additional measures described above were candidates for 
model inclusion. To achieve model parsimony, backward variable selection procedures were 
used to eliminate non-clinical variables that did not reach statistical significance level of 
0.10. All analyses were adjusted for geographic location (Los Angeles versus Detroit). Odds 
ratios (OR) and 95% confidence intervals (95% CI) were calculated and presented. The F 
tests were used to examine the overall association of independent variables with the outcome 
of interest. Finally, we used descriptive statistics to examine reported reasons for non-
initiation of and non-persistence with adjuvant endocrine therapy.
Survey Weighting—In the initial descriptive statistics and multivariable models, we 
incorporated survey weights to make our statistical inference representative of the 
population. We created design weights to account for oversampling of blacks and Latinas, as 
well as disproportionate selection across locations. We also weighted the sample for non-
response to recognize that certain patient characteristics are likely to influence response to 
both the baseline and follow up questionnaire. Multivariable logistic regression models were 
used to create the non-response weights, with the final weight calculated as the product of 
the design and non-response weights. All statistical tests were two-sided, and a p value less 
than .05 was considered statistically significant. All analyses were performed using STATA 
(College Station, TX).
Results
These analyses are based on 743 respondents with invasive disease (see Figure for details on 
how the analytic sample was derived). 1,536 women completed both the baseline and follow 
up surveys. To restrict our sample to women who met clinical indications for endocrine 
therapy, we excluded 793 respondents: those who did not have invasive disease (n = 381), 
had negative or unknown ER and/or PR receptor status (n = 315), had experienced a 
recurrence at the time of our follow up survey (n = 42), or had incomplete data on study 
measures (n = 55).
Of the 743 women in our analytic sample, 663 (89.2%) initiated endocrine therapy. Of those 
who initiated therapy, 551 (83.1%) were persistent with therapy at approximately four years 
after diagnosis (74.2% of the entire analytic sample). Table 1 shows the characteristics of 
the study sample and the distribution of the outcome variables, initiation and persistence. In 
the bivariate analyses, significant differences were observed on rates of endocrine therapy 
initiation by age, SEER tumor grade, the presence of comorbid conditions, worry about 
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recurrence score, receipt of information about endocrine therapy, and primary provider for 
cancer care follow up. Initiation rates varied by the presence of comorbid conditions (p < .
01) with 82%, 94% and 90% for women with 2 or more conditions, one condition and none 
respectively. The degree of worry about recurrence was significantly associated with the rate 
of initiation (p=0.02); patients with higher worry about recurrence had higher rates of 
initiation (93%, 89% and 83% for high, medium and low worry scores, respectively).
In bivariate analyses (Table 1), fewer variables differed significantly on the persistence 
outcome. Weekly medication use was associated with different rates of persistence (p<.001) 
with 87% of patients who took 2 or more medications weekly persisted on therapy, 
compared with a persistence rate of 68% for women who took fewer than two medications 
weekly. Higher scores on the worry about recurrence scale were associated with 
significantly higher rates of persistence (p = .05). Those who reported they did not receive 
adequate information about endocrine therapy had lower rates of persistence (77 vs. 84%, p 
< .001).
Factors associated with endocrine therapy initiation
After backward variable selection procedures, several variables were removed from the 
initiation model, including tumor size, comorbid conditions, education, marital status, and 
the medication beliefs scale. The final weighted multivariable model is presented in Table 2. 
Initiation of therapy was associated with Latina ethnicity (OR 2.80, 95% CI 1.08-7.23), 
black race vs. non-Hispanic white (OR 3.63, 95% CI 1.22 – 10.78), and grade 2 tumors 
(versus Grade 1, OR 2.59, 95% CI 1.13-5.94). Women with higher scores on the worry 
about recurrence scale were more likely to report initiation (Medium vs. Low OR 2.25, 95% 
CI 1.06-4.82; High vs. Low OR 3.54, 95% CI 1.31-9.56), as were women who reported their 
primary provider for cancer follow up was a medical oncologist rather than a surgeon (OR 
3.21, 95% CI 1.02-9.60). Women who reported they had received inadequate information 
about endocrine therapy were significantly less likely to initiate treatment than women who 
did not report inadequate information (OR 0.25, 95% CI 0.10-0.55). Age and tumor stage 
were not significantly associated with initiation.
Factors associated with endocrine therapy persistence at four years
Table 3 shows the weighted multivariable model for persistence with measures retained after 
backward variable selection procedures. Lower likelihood of persistence was associated 
significantly with increasing age (OR 0.98, OR 0.95-1.00, p < .04). Compared with those 
who reported taking none or one medication weekly, women who took two or medications 
weekly as reported in the follow up survey were more likely to persist on therapy (OR 4.19, 
95% CI 2.28-7.68). No significant differences in persistence were observed by race/
ethnicity, tumor stage, tumor grade, worry about recurrence, or type of provider for follow 
up oncology care.
Reasons for non-initiation and non-persistence
Therapy-eligible participants who never initiated therapy (n = 80) were asked why they did 
not, and these unweighted descriptive responses are shown in Table 4a. Participants could 
choose multiple responses. Clinician factors were primarily cited, including statements such 
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as doctor said they did not need therapy (n=27, 33.8%), or the doctor left it up to the patient 
(n=17, 21.3). Reported patient factors included concerns about side effects (n=23, 28.8%) 
and cost (n=4, 5.0%). Patient factors were cited by many of the 112 women who 
discontinued treatment; 45 (40.2%) cited side effects, 28 (25%) cited concerns about the 
risks from the medication, and 26 (23.2%) reported a general dislike of medication (see 
Table 4b).
Discussion
The majority of women in our population based sample eligible for endocrine therapy both 
initiated and persisted on therapy: of the 743 patients eligible for endocrine therapy, 80 
(10.8%) never initiated therapy, 112 (15.1%) started therapy but discontinued prematurely, 
and 551 (74.2%) continued use at the second time point. Our findings are consistent with 
previously published reports. A study that used commercial claims data to assess adherence 
with adjuvant anastrozole therapy [8] showed that women enrolled in three different 
insurance plans had adherence rates of 62-79% by the third year of treatment. Women in our 
study were treated more recently (2005-2010) compared with a timeframe of 2002-2004 in 
above-cited study [8]. A single-site study performed in 2006 reported similar rates of 
initiation and persistence [39].
Blacks and Latinas had the highest rates of initiation and persistence in our sample. Ours is 
not the first study to document null findings or higher rates of treatment completion in 
groups historically considered disadvantaged. Recent reports have documented the absence 
of racial disparities in adjuvant endocrine therapy in the Medicare [40] and Medicaid [41] 
populations, as well in the receipt of systemic chemotherapy [34, 42]. Poverty, insurance 
coverage, family support, and overall treatment experiences are contextual factors that may 
explain endocrine therapy persistence [43-46]. Our study did not examine the effects of peer 
support or breast cancer navigator programs, both of which may have supported black and 
Latinas through treatment during the study period.
Patients who initiated endocrine therapy expressed more worry about recurrence, regardless 
of tumor stage and grade. While clinicians educate patients to mitigate the anxiety 
surrounding a breast cancer diagnosis, health behaviorists assert that perceived susceptibility 
is a strong motivator for desired health behaviors [47]. In our study and in a report by others 
[25], women who reported receiving less information about endocrine therapy were less 
likely to initiate therapy. Adequacy of information was associated with initiation but not 
persistence. This suggests that clinicians need to address patient information needs regarding 
therapy prior to initiation of treatment. Treatment initiation was higher for women who saw 
medical oncologists as opposed to other providers for their follow-up cancer care. It is likely 
that patients who saw medical oncologists may have clearer indications for endocrine 
therapy. Other providers of follow up oncology care may benefit from additional education 
or resources to support patients receiving endocrine therapy. Women who took two or more 
medications at the time of the follow up survey were more likely to persist with endocrine 
therapy, which suggests that women who were less experienced in medication use prior to a 
breast cancer diagnosis may be at risk for low persistence.
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Patients who did not initiate treatment cited provider factors as the primary reason. These 
responses likely reflect physician judgment that endocrine therapy is not warranted in these 
cases. It is interesting to note that few patients endorsed insurance coverage as a reason for 
not starting therapy, despite the findings from previous investigators [48]. However, a total 
of 32 patients cited drug expense or insurance issues as one of many reasons for not 
initiating or persisting with therapy. In our sample, patient attitudes about endocrine therapy 
and medication in general were associated with premature termination. Side effects, safety 
concerns, and a general dislike of medication were the most often-cited factors. Severe side 
effects were the largest predictor of discontinuation of tamoxifen in a prior study [25]. These 
findings from a population-based sample of patients are timely considering the ATLAS trial 
results reported at the 2012 San Antonio Breast Cancer Symposium. In this clinical trial, 
women who completed 10 years of adjuvant tamoxifen therapy compared with five years 
had significantly lower recurrence and breast cancer mortality rates [13]. Outside of a 
clinical trial, clinicians may be challenged to maintain patients on therapy for ten years if 
side effects are a key barrier to persistence. Aggressive supportive care and consultation 
with oncology pharmacists may be important interventions to consider if the duration of 
endocrine therapy is extended in forthcoming clinical practice guidelines.
There are several limitations of this study. First, we relied on patient self-report of initiation 
and persistence to endocrine therapy. We were unable to ascertain if patients who did not 
initiate were not offered a prescription for endocrine therapy. Measurement of medication 
use with prescription data or the clinical record would strengthen the validity of our findings 
[49]. The data derived from a sample of women who completed surveys at approximately 9 
months and 4 years after breast cancer diagnosis. Our sample of women is more likely to 
persist on therapy than women in the general population. Because routine medication use 
was measured only at the 4-year follow up survey, we cannot assess the degree to which 
routine medical use influences initiation of therapy. Another limitation of this study is that 
the study participants were recruited from only two sites—Los Angeles county and 
Metropolitan Detroit—with three racial and ethnic groups: white, black, and Latina women. 
While our study sample is diverse, findings may not be generalizable to other populations or 
geographic settings.
In conclusion, adjuvant endocrine therapy initiation and persistence rates are high in a 
diverse population-based sample of eligible women. Differences by socioeconomic status 
are small. Initiation is influenced by worry about recurrence, sufficient information receipt 
about these agents, and primary source of cancer care during treatment with endocrine 
therapy. Persistence is associated with younger age and concurrent medication use. Care 
settings without medical oncologists may benefit from additional resources to support 
eligible patients. Non-persistence was largely related to patient attitudes toward therapy. 
These findings highlight the need for additional education and support strategies for women 
– regardless of race or ethnicity – at risk for not initiating or persisting on adjuvant 
endocrine therapy to optimize treatment and reduce breast cancer recurrence and improve 
survival.
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Table 1











Age, mean (SD) 58.9 (11.7) 57.5 (11.2) .05 57.1 (11.1) .11
Education .59 .26
High school or less 264 (39.9) 90 82
Some college 253 (33.2) 87 82
College graduate + 217 (26.8) 91 88
Race .46 .10
White 409 (48.3) 87 81
Latina 183 (37.6) 91 88
Black 140 (14.2) 91 78
SEER Stage .31 .21
Stage I 395 (48.5) 88 81
Stage II 263 (38.6) 89 84
Stage III 83 (12.9) 93 91
SEER Grade <.01 .07
Grade 1 177 (21.8) 85 81
Grade 2 326 (45.7) 94 84
Grade 3 193 (25.6) 86 91
Unknown Grade 47 (6.9) 100 50
Comorbid Conditions <.01 .57
None reported 297 (40.0) 90 83
One reported 223 (31.1) 94 85
2 or more reported 223 (28.8) 82 81
Number of medications taken
in the week prior to the follow up survey
<.001
0-1 157 (21.6) 68
2 or more 578 (78.5) 87
Medication Beliefs
Scale, mean (SD)
2.91(0.57) 2.83 (0.59) 0.28 2.82 (0.59) .13
Worry about Recurrence Score .020 .05
Low (≤ 2.0) 154 (18.7) 83 81
Medium (2.1-
4.0)
413 (54.5) 89 81
High (> 4.0) 174 (26.8) 93 90
Received enough information about endocrine
therapy
<.001 <.001
Yes 622 (83.8) 92 84
No 110 (16.2) 74 77
Primary Oncology Provider <.01 .14
Surgeon 46 (6.3) 84 77
























Medical 561 (77.2) 94 87
Oncologist
Other provider 136 (16.5) 70 65
Note: Values weighted to account for differential probabilities of sample selection and non-response.
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Table 2










Stage I 1.0 ref .35
Stage II 1.62 0.76-3.51
Stage III 1.84 0.55-6.19
SEER Grade
Grade 1 1.0 ref <.001
Grade 2 2.59 1.13-5.94
Grade 3 1.84 0.55-6.19
Age 1.00 0.97-1.04 .80
Worry about Recurrence Score
Low 1.0 ref .03
Medium 2.25 1.06-4.82
High 3.54 1.31-9.56
Received enough information about endocrine
therapy
Yes 1.0 ref <.001
No 0.24 0.10-0.55
Primary Oncology Provider
Surgeon 1.0 ref <.001
Medical Oncologist 3.12 1.02-9.60
Other Provider 0.44 0.14-1.40
Note: Parameter estimates weighted to account for differential probabilities of sample selection and non-response.
Model includes adjustment for SEER site (Detroit vs. Los Angeles)
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Table 3









Stage I 1.0 ref
Stage II 1.37 0.76-2.46 .37
Stage III 1.90 0.65-5.59
SEER Grade
Grade 1 1.0 ref .06
Grade 2 1.18 0.58-2.39
Grade 3 0.55 0.25-1.20
Age 0.98 0.95-1.00 .04
Number of medications taken
in the week prior to the follow up survey
0-1 1.0 ref <.001
2 or more 4.19 2.28-7.68
Worry about Recurrence Score




Surgeon 1.0 ref .11
Medical Oncologist 1.44 0.51-4.04
Other Provider 0.40 0.13-1.22
Note: Parameter estimates weighted to account for differential probabilities of sample selection and non-response.
Model includes adjustment for SEER site (Detroit vs. Los Angeles)
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Table 4a




Doctor said I did not need 27 (33.8)
Doctor left it up to me 17 (21.3)
Doctor never discussed 6 (7.5)
Patient Factors
Worried about side effects 23 (28.8)
Doctor recommended, but
I chose not to
15 (18.8)
Too expensive 4 (5.0)













Friese et al. Page 18
Table 4b




Side Effects 45 (40.2)
Worried about risks 28 (25.0)
Dislike medication 26 (23.2)
I wasn’t sure if it was helping 25 (22.3)
Too expensive 21 (18.8)
I’d taken it long enough 20 (17.9)
I wanted to move on from cancer 14 (16.1)
I stopped for insurance reasons 8 (7.1)
Clinician Factors
Doctor told me to stop 28 (25.0)
Completed course of treatment 14 (12.5)
Note. Percentages do not add up to 100% as participants could choose multiple responses.
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